Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
2cureX AB Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.	Sweden	2CUREX
4BASEBIO PLC Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.	United Kingdom	4BB
4SC AG Developing small-molecule epigenetic drugs for high-need cancer indications.	Germany	VSC
60 DEGREES PHARMACEUTICALS, INC. Develops medicines for tropical diseases, including ARAKODA for malaria prevention.	United States of America	SXTP
89bio, Inc. Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.	United States of America	ETNB
Aardvark Therapeutics, Inc. Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.	United States of America	AARD
AbbVie Inc. A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.	United States of America	ABBV
ABEONA THERAPEUTICS INC. Developing AAV-based cell and gene therapies for serious and rare diseases.	United States of America	ABEO
Abera Bioscience AB Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.	Sweden	ABERA
ABINGDON HEALTH PLC A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.	United Kingdom	ABDX